Skip to main content

Table 3 NT-proBNP values in pmol/L

From: The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study

 

pimobendan (A) treatment

placebo (B) treatment

baseline

day 90

day 180

baseline

day 90

day 180

pre-exercise

700.1 (± 401.3)

478.5 (± 291)

540.9 (± 327.1)

756.1 (± 399.7)

695.2 (± 531.1)

704.5 (± 469.9)

post-exercise

774.1 (± 368.7)

555.9 (± 300.5)

545.7 (± 371.9)

869.8 (± 492.2)

762.2 (± 592.1)

770.8 (± 521.3)

increase

74 (± 103.7)

77.4 (± 86.7)

4.7 (± 85.4)

113.7 (± 157.3)

67 (± 96.1)

66.3 (± 151.2)

  1. NT-proBNP values for 15 dogs under the treatment with pimobendan and placebo. For the baseline- and follow-up-investigations at day 90 and 180 in each treatment period, the pre- and post-exercise NT-proBNP values are given together with their increase
Back to article page

BMC Veterinary Research

ISSN: 1746-6148

Contact us